Combined intensive chemotherapy and radical surgery for incurable gastric cancer
| Autor: | Yasuhiko Ohashi, Toshifusa Nakajima, Shou Ishihara, Shigekazu Oyama, Mitsumasa Nishi, Keiichiro Ota, Akio Yanagisawa |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Adult
Male medicine.medical_specialty medicine.medical_treatment Leucovorin Adenocarcinoma Metastasis Surgical oncology Gastrectomy Stomach Neoplasms Antineoplastic Combined Chemotherapy Protocols medicine Humans Radical surgery Survival rate Etoposide Aged Epirubicin Chemotherapy business.industry Cancer Middle Aged medicine.disease Combined Modality Therapy Surgery Survival Rate Logistic Models Oncology Female Fluorouracil Cisplatin business Progressive disease medicine.drug |
| Zdroj: | Annals of surgical oncology. 4(3) |
| ISSN: | 1068-9265 |
| Popis: | Background: To improve the poor prognosis of patients with advanced incurable gastric cancer, intensive chemotherapy combined with radical surgery was used. Patients and Methods: Thirty patients with incurable gastric cancer were treated with a combination of 5-fluorouracil (370 mg/m2) and leucovorin (30 mg/person), given intravenously for five consecutive days, followed by cisplatinum (70 mg/m2) and etoposide (70 mg/m2) on days 6 and 20, delivered through a catheter placed either in the aorta with its tip at the level of the ninth thoracic vertebra or in the celiac artery. This treatment (FLEP therapy) was repeated twice every 5 weeks. Radical or palliative surgery followed chemotherapy. Results: The overall response rate to the chemotherapy was 50.0% (15 of 30 patients, 95% confidence limit 0.305–0.671). Nineteen patients (15 with a partial response, three showing no change, and one with progressive disease) underwent surgery. Of these, nine underwent curative surgery and 10 palliative surgery. The median survival time was 6.5 months overall, 12.7 months for responders, and 4.7 months for nonresponders. Long-term survivors were exclusively found among patients with distant lymph node metastasis treated by curative surgery (55.6% at 5 years). Conclusions: Favorable results of this small phase II study justify a phase III trial. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink